Article

ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.

 

See more ASCRS conference coverage here 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Ophthalmologists present data on perfluorohexyloctane eye drops
August 14th 2025

Ophthalmologists present data on perfluorohexyloctane eye drops

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
August 14th 2025

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery
August 14th 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery

EyePod
August 14th 2025

ASCRS 2020: Assessing aberration of monofocal toric IOL with enhanced optic recovery, alignment

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
August 14th 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
August 14th 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

© 2025 MJH Life Sciences

All rights reserved.